Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn the STEP 1 trial, adults taking semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks (roughly 15kg for someone starting at 100kg) alongside a reduced-calorie diet and increased activity. That figure comes from the STEP 1 study published in the New England Journal of Medicine, and it is the most reliable answer to how much weight you lose on Wegovy: significant for many people, but not identical for everyone. If you are now wondering what that kind of treatment costs in the UK, you are in the right place. Wegovy is a prescription-only medicine, which means a prescriber must assess your suitability before any treatment begins — and that clinical step shapes what legitimate pricing looks like.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You read the trial numbers. You may have spoken to someone who lost weight on Wegovy. Now you're pricing it up, and you've noticed the figures vary quite a bit between providers. That variation is real, and it has a straightforward explanation.
Private Wegovy treatment in the UK is priced per pen or per month, and it moves through several dose steps before reaching the 2.4mg maintenance level (or, for eligible patients, the newer 7.2mg dose approved by the MHRA in April 2026). Earlier steps in the titration schedule cost less; higher maintenance doses cost more. Eli Lilly's September 2025 list-price increase for Mounjaro drew press attention, but Novo Nordisk's pricing for Wegovy has also shifted across the private market. Typically, private semaglutide treatment ranges roughly £149 to £375 per month depending on dose and provider, as widely reported since those changes came into force. Those figures are the market context, not a promise of what you will pay anywhere.
A quick check worth doing before you commit to any online provider: search the GPhC pharmacy register for the pharmacy's name or registration number. It takes under a minute, and a pharmacy that is not listed there should not be supplying prescription medicines to UK patients. nume's GPhC premises registration is 9012878, verifiable directly on that register.
The lowest figure on a search results page rarely survives contact with the checkout. Common additions that raise the real cost of Wegovy treatment elsewhere include: a separate consultation fee (sometimes £20–£50), a prescription charge on top of the medicine price, a delivery fee per order, and aftercare or dose-review fees charged as extras or bundled into a subscription you cannot pause.
Some providers also require a paid subscription before you can place a repeat order, which means the month you choose not to continue still costs you. That is worth reading the small print on. Wegovy pricing in the UK is a topic we cover in detail, including what drives the differences between providers. For a longer view of the numbers, our page on Wegovy's annual cost works through what a full year of treatment adds up to across different scenarios.
Clinical aftercare is also sometimes absent from cheaper offerings. For a medicine that requires dose titration, side-effect management and regular weight checks, the absence of accessible clinical support is not a minor omission.
We are not the cheapest option. That is a deliberate decision. A single transparent price at nume covers the consultation, the prescription, the medicine, and next-working-day tracked delivery, nothing added at the end. There are no subscription fees; every repeat order is clinically re-reviewed by a GPhC-registered prescriber before dispatch, and priority aftercare is available seven days a week if you have questions between orders.
Our clinical team (you can read about the people behind nume's prescribing on our clinical team page) reviews every consultation personally. Not software. A prescriber reads your answers, checks your eligibility, and makes a clinical decision. That process is what NHS England's guidance on weight-management injections describes as the appropriate standard of care, and it is what any legitimate private provider should be matching.
Current treatment pricing is shown on our weight-loss treatments page. We do not print per-pen prices in article copy, because the right price for you depends on which dose you are on, and that is a clinical question, not a menu choice. If you want to explore how the results evidence varies across the dose schedule, our guide to how much weight you can lose on the 0.5mg starting dose is a useful place to begin, and if you are further along and want to understand the full picture, the broader Wegovy weight-loss results guide covers both in detail, including a look at how much you personally might expect to lose on Wegovy based on the available evidence, as well as a dedicated page on how much weight you can lose at the 2.4mg maintenance dose for those approaching or already on that level.
The MHRA has warned repeatedly about counterfeit weight-loss pens circulating online, including fake semaglutide and tirzepatide pens seized in large quantities from unregulated sellers, some containing insulin. Sellers offering these medicines without a clinical assessment or at prices far below the market are a documented safety risk. Report anything suspicious through the MHRA's Yellow Card scheme, which accepts reports from patients as well as clinicians.
For a prescription medicine that works by acting on gut-hormone receptors to suppress appetite and slow gastric emptying, the real questions are whether the supply chain is genuine, whether a qualified prescriber assessed your suitability, and whether clinical support is there if something does not feel right. A smaller monthly outlay answers none of those questions. It just moves the risk onto you.
If you are ready to find out whether Wegovy is clinically suitable for your situation, speak to our prescribers, the consultation is free, and you will hear back the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.